Human Laboratory Studies for Stimulant Addiction

描述（由申请人提供）：此K 02重新提交寻求Mehmet Sofuoglu，M.D.的工资支持，博士候选人拥有博士学位。他在药理学方面有着丰富的经验，并在行为药理学方面积累了丰富的经验，包括在人体内进行可卡因和尼古丁的静脉注射激发研究。他目前是耶鲁大学医学院精神病学副教授。Sofuoglu博士建立了一个创新的研究计划，开发可卡因和尼古丁成瘾的新型药物治疗。他在尼古丁和可卡因成瘾方面的工作建立了强大的出版记录，国家认可和独立资金。他的主要研究兴趣是：1）性别和月经周期对兴奋剂成瘾影响的神经生物学机制和2）GABA和肾上腺素能系统作为兴奋剂成瘾药物治疗的靶点。在未来5年内，候选人将专注于两个R 01项目。第一个项目“GABA药物和烟草成瘾”是一项人体实验室研究，将研究GABA增强药物噻加宾对男性和女性吸烟者吸烟行为、烟草戒断严重程度和吸烟渴望的剂量依赖性影响。第二个项目“可卡因戒断和药物治疗反应”是一项门诊临床试验，将评估β-和α-肾上腺素能阻滞剂卡维地洛对可卡因成瘾药物治疗的疗效。这两个项目都符合候选人对成瘾性疾病药物开发的长期研究兴趣。候选人正在寻求K 02奖，以接受进一步的培训，并获得其他领域的专业知识，这将进一步扩大他的研究范围，包括性激素和神经类固醇的神经生物学，以及临床试验方法。为了实现这些培训目标，候选人提出了一个教育计划，包括课程和具有相关专业知识的资深同事的指导。此K 02应用程序将提供支持候选人在可卡因和尼古丁成瘾领域的持续研究。

DESCRIPTION (provided by applicant): This K02 re-submission seeks salary support for Mehmet Sofuoglu, M.D., Ph.D. The candidate has a Ph.D. in pharmacology and has developed expertise in behavioral pharmacology including intravenous challenge studies with cocaine and nicotine in humans. He is currently an Associate Professor of Psychiatry at the Yale University School of Medicine. Dr. Sofuoglu has built an innovative research program on development of novel pharmacological treatments for cocaine and nicotine addiction. He has established a strong publication record, national recognition, and independent funding for his work in nicotine and cocaine addiction. His main research interests are: 1) neurobiological mechanisms of sex and menstrual cycle effects on stimulant addiction and 2) the GABA and adrenergic system as targets for the pharmacotherapy of stimulant addiction. During the next 5 years, the candidate will focus on two R01 projects. The first project, "GABA Medications and Tobacco Addiction" is a human laboratory study and will examine the dose-dependent effects of GABA enhancing medication tiagabine on smoking behavior, tobacco withdrawal severity, and craving for cigarettes in male and female smokers. The second project "Cocaine Withdrawal and Pharmacotherapy Response" is an outpatient clinical trial and will evaluate the efficacy of a beta- and alpha- adrenergic blocker, carvedilol for pharmacotherapy of cocaine addiction. Both these projects are consistent with the candidate's long-term research interest in medications development for addictive disorders. The candidate is seeking a K02 award to receive further training and gain expertise in other fields that will further expand his research scope including neurobiology of sex hormones and neurosteroids, and clinical trials methodology. To reach these training goals, the candidate proposes an educational program including coursework and mentoring from senior colleagues with relevant expertise. This K02 application will provide support for the candidate's sustained research in areas of cocaine and nicotine addiction.